Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DBTX Decibel Therapeutics (DBTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Decibel Therapeutics Stock (NASDAQ:DBTX) 30 days 90 days 365 days Advanced Chart Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Decibel Therapeutics alerts:Sign Up Key Stats Today's Range$4.90▼$5.1150-Day Range$4.91▼$5.2352-Week Range$1.61▼$5.40Volume1.26 million shsAverage Volume122,002 shsMarket Capitalization$123.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDecibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts. As of September 25, 2023, Decibel Therapeutics, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Receive DBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DBTX Stock News HeadlinesBest Earplugs to Prevent Hearing Loss for 2024August 28, 2024 | cnet.comThe Best White Noise Machines That Drown Out Sounds For Better SleepAugust 3, 2024 | forbes.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Best Noise-Canceling Headphones Under $100 for 2024March 28, 2024 | cnet.comNoise-Induced Hearing Loss in Kids Is a Growing Problem. Here’s How to Protect Little Ears.March 5, 2024 | nytimes.comSound Machines Aren’t Just for Sleep. Here’s How to Use Brown Noise to Focus at Work.February 14, 2024 | nytimes.comThe Best Noise-Cancelling HeadphonesNovember 17, 2023 | nytimes.comDecibel Therapeutics' CVR Appears Around Fair ValueSeptember 15, 2023 | seekingalpha.comSee More Headlines DBTX Stock Analysis - Frequently Asked Questions How were Decibel Therapeutics' earnings last quarter? Decibel Therapeutics, Inc. (NASDAQ:DBTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by $0.23. When did Decibel Therapeutics IPO? Decibel Therapeutics (DBTX) raised $100 million in an initial public offering on Friday, February 12th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO. What other stocks do shareholders of Decibel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Decibel Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Wells Fargo & Company (WFC), Bank of America (BAC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT). Company Calendar Last Earnings11/10/2021Today11/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:DBTX CUSIPN/A CIK1656536 Webdecibeltx.com Phone617-370-8701FaxN/AEmployees68Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-84.03% Return on Assets-53.90% Debt Debt-to-Equity RatioN/A Current Ratio3.03 Quick Ratio3.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.28 per share Price / Book1.50Miscellaneous Outstanding Shares25,130,000Free Float16,182,000Market Cap$123.39 million OptionableNot Optionable Beta-0.43 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:DBTX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Decibel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Decibel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
